Pediatric Infratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Infratentorial Ependymoma

MalaCards integrated aliases for Pediatric Infratentorial Ependymoma:

Name: Pediatric Infratentorial Ependymoma 12 15
Childhood Infratentorial Ependymoma 71


External Ids:

Disease Ontology 12 DOID:7501
NCIt 49 C9041
UMLS 71 C0278599

Summaries for Pediatric Infratentorial Ependymoma

MalaCards based summary : Pediatric Infratentorial Ependymoma, also known as childhood infratentorial ependymoma, is related to benign ependymoma and cellular ependymoma, and has symptoms including vomiting, headache and nausea. An important gene associated with Pediatric Infratentorial Ependymoma is NELL2 (Neural EGFL Like 2). The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include brain and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pediatric Infratentorial Ependymoma

Diseases related to Pediatric Infratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 benign ependymoma 10.2
2 cellular ependymoma 10.2
3 ataxia and polyneuropathy, adult-onset 10.1
4 dysphagia 10.1
5 hypotonia 10.1
6 uterine inflammatory disease 9.3 SNORD96A SNORD61

Graphical network of the top 20 diseases related to Pediatric Infratentorial Ependymoma:

Diseases related to Pediatric Infratentorial Ependymoma

Symptoms & Phenotypes for Pediatric Infratentorial Ependymoma

UMLS symptoms related to Pediatric Infratentorial Ependymoma:

vomiting, headache, nausea

GenomeRNAi Phenotypes related to Pediatric Infratentorial Ependymoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.36 LAMA2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-131 9.36 LAMA2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 NELL2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 9.36 LAMA2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.36 LAMA2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.36 LAMA2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-210 9.36 NELL2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 LAMA2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-9 9.36 NELL2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 9.36 LAMA2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-96 9.36 NELL2

Drugs & Therapeutics for Pediatric Infratentorial Ependymoma

Drugs for Pediatric Infratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
leucovorin Approved Phase 3 58-05-9 6006 143
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
Ondansetron Approved Phase 3 99614-02-5 4595
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Histamine Approved, Investigational Phase 3 51-45-6 774
Cyproheptadine Approved Phase 3 129-03-3 2913
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Vitamin B Complex Phase 3
14 Folic Acid Antagonists Phase 3
15 Folate Phase 3
16 Dermatologic Agents Phase 3
17 Antirheumatic Agents Phase 3
18 Antimetabolites Phase 3
19 Vitamin B9 Phase 3
20 Tubulin Modulators Phase 3
21 Antimitotic Agents Phase 3
22 Antiemetics Phase 3
23 Emetics Phase 3
24 Gastrointestinal Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Histamine Antagonists Phase 3
27 Anti-Allergic Agents Phase 3
Histamine Phosphate Phase 3 51-74-1 65513
29 Histamine H1 Antagonists Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
Sodium citrate Approved, Investigational Phase 2 68-04-2
Tamoxifen Approved Phase 2 10540-29-1 2733526
Carmustine Approved, Investigational Phase 2 154-93-8 2578
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
Iodine Approved, Investigational Phase 2 7553-56-2 807
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
Promethazine Approved, Investigational Phase 2 60-87-7 4927
Acetaminophen Approved Phase 2 103-90-2 1983
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49 Hormone Antagonists Phase 2
50 Hormones Phase 2

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
5 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
7 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
8 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
9 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
10 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
11 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
12 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
13 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
14 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
15 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
16 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
17 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
18 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
19 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
20 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
21 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
22 Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors Completed NCT00098761 Phase 1 laromustine
23 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
24 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
25 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
26 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
27 A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors Completed NCT00107458 Phase 1 valproic acid
28 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
29 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
30 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
31 A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
32 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
33 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
34 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
35 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
36 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
37 Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
38 A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias Withdrawn NCT00458744 Phase 1 talotrexin
39 Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121 Completed NCT01407744
40 Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors Completed NCT00006342
41 Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma Completed NCT00303810 carboplatin;cisplatin;cyclophosphamide;etoposide phosphate;high-dose chemotherapy;lomustine;methotrexate;thiotepa;vincristine sulfate
42 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
43 Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma HGNET, CNS Embryonal Tumors and Gliomas of the Pediatric CNS Recruiting NCT00897286
44 CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday Active, not recruiting NCT00683319 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
45 Immunologic Profile of Patients With Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy Withdrawn NCT01233479 systemic chemotherapy
46 Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Pediatric Infratentorial Ependymoma

Genetic Tests for Pediatric Infratentorial Ependymoma

Anatomical Context for Pediatric Infratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Infratentorial Ependymoma:

Brain, Liver

Publications for Pediatric Infratentorial Ependymoma

Articles related to Pediatric Infratentorial Ependymoma:

# Title Authors PMID Year
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 61
27390862 2016
Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. 61
21863401 2012
Evolution of neurological impairment in pediatric infratentorial ependymoma patients. 61
19330288 2009
Cervical subluxation after surgery and irradiation of childhood ependymoma. 61
12006754 2002
Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. 61
11672779 2001

Variations for Pediatric Infratentorial Ependymoma

Expression for Pediatric Infratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Infratentorial Ependymoma.

Pathways for Pediatric Infratentorial Ependymoma

GO Terms for Pediatric Infratentorial Ependymoma

Sources for Pediatric Infratentorial Ependymoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....